Matthew Reynolds to Risk Assessment
This is a "connection" page, showing publications Matthew Reynolds has written about Risk Assessment.
Connection Strength
1.118
-
Reynolds MR. Outcomes with digoxin in atrial fibrillation: more data, no answers. J Am Coll Cardiol. 2014 Aug 19; 64(7):669-71.
Score: 0.269
-
Reynolds MR. Discontinuation of rivaroxaban: filling in the gaps. J Am Coll Cardiol. 2013 Feb 12; 61(6):659-60.
Score: 0.243
-
Zeitler EP, Bian B, Griffiths RI, Allocco DJ, Christen T, Roy K, Cohen DJ, Reynolds MR. Long-Term Clinical Outcomes Following the WATCHMAN Device Use in Medicare Beneficiaries. Circ Cardiovasc Qual Outcomes. 2024 Oct; 17(10):e011007.
Score: 0.136
-
Arnold SV, Spertus JA, Vemulapalli S, Li Z, Matsouaka RA, Baron SJ, Vora AN, Mack MJ, Reynolds MR, Rumsfeld JS, Cohen DJ. Quality-of-Life Outcomes After Transcatheter Aortic Valve Replacement in an Unselected Population: A Report From the STS/ACC Transcatheter Valve Therapy Registry. JAMA Cardiol. 2017 04 01; 2(4):409-416.
Score: 0.081
-
Chyou JY, Hunter TD, Mollenkopf SA, Turakhia MP, Reynolds MR. Individual and Combined Risk Factors for Incident Atrial Fibrillation and Incident Stroke: An Analysis of 3 Million At-Risk US Patients. J Am Heart Assoc. 2015 Jul 23; 4(7).
Score: 0.072
-
Kramer DB, Friedman PA, Kallinen LM, Morrison TB, Crusan DJ, Hodge DO, Reynolds MR, Hauser RG. Development and validation of a risk score to predict early mortality in recipients of implantable cardioverter-defibrillators. Heart Rhythm. 2012 Jan; 9(1):42-6.
Score: 0.055
-
Witte KK, Tsivgoulis G, Reynolds MR, Tsintzos SI, Eggington S, Ismyrloglou E, Lyon J, Huynh M, Egea M, de Brouwer B, Ziegler PD, Franco N, Joglekar R, Rosemas SC, Liu S, Thijs V. Burden of oral anticoagulation in embolic stroke of undetermined source without atrial fibrillation. BMC Cardiovasc Disord. 2021 03 31; 21(1):160.
Score: 0.027
-
Resnic FS, Majithia A, Dhruva SS, Ssemaganda H, Robbins S, Marinac-Dabic D, Hewitt K, Ohno-Machado L, Reynolds MR, Matheny ME. Active Surveillance of the Implantable Cardioverter-Defibrillator Registry for Defibrillator Lead Failures. Circ Cardiovasc Qual Outcomes. 2020 04; 13(4):e006105.
Score: 0.025
-
Barker CM, Reardon MJ, Reynolds MR, Feldman TE. Association Between Institutional Mitral Valve Procedure Volume and Mitral Valve Repair Outcomes in Medicare Patients. JACC Cardiovasc Interv. 2020 05 11; 13(9):1137-1139.
Score: 0.025
-
Field ME, Gold MR, Reynolds MR, Goldstein L, Lee SHY, Kalsekar I, Coplan P, Wong C, Khanna R, Winterfield JR. Real-world outcomes of ventricular tachycardia catheter ablation with versus without intracardiac echocardiography. J Cardiovasc Electrophysiol. 2020 02; 31(2):417-422.
Score: 0.024
-
Galper BZ, Reynolds MR, Garg P, Secemsky EA, Valsdottir LR, Cohen DJ, Yeh RW. Cost-effectiveness analysis of short-duration dual antiplatelet therapy with newer drug-eluting stent platforms versus longer-duration dual antiplatelet therapy with a second-generation drug-eluting stent in elective percutaneous coronary intervention. Coron Artery Dis. 2019 05; 30(3):177-182.
Score: 0.023
-
Baron SJ, Wang K, House JA, Magnuson EA, Reynolds MR, Makkar R, Herrmann HC, Kodali S, Thourani VH, Kapadia S, Svensson L, Mack MJ, Brown DL, Russo MJ, Smith CR, Webb J, Miller C, Leon MB, Cohen DJ. Cost-Effectiveness of Transcatheter Versus Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Intermediate Risk. Circulation. 2019 02 12; 139(7):877-888.
Score: 0.023
-
Lubitz SA, Khurshid S, Weng LC, Doros G, Keach JW, Gao Q, Gehi AK, Hsu JC, Reynolds MR, Turakhia MP, Maddox TM. Predictors of oral anticoagulant non-prescription in patients with atrial fibrillation and elevated stroke risk. Am Heart J. 2018 06; 200:24-31.
Score: 0.022
-
Arnold SV, Reynolds MR, Wang K, Magnuson EA, Baron SJ, Chinnakondepalli KM, Reardon MJ, Tadros PN, Zorn GL, Maini B, Mumtaz MA, Brown JM, Kipperman RM, Adams DH, Popma JJ, Cohen DJ. Health Status After Transcatheter or Surgical Aortic Valve Replacement in Patients With Severe Aortic Stenosis at Increased Surgical Risk: Results From the CoreValve US Pivotal Trial. JACC Cardiovasc Interv. 2015 Aug 17; 8(9):1207-1217.
Score: 0.018
-
Schneider PM, Pellegrini CN, Wang Y, Fein AS, Reynolds MR, Curtis JP, Masoudi FA, Varosy PD. Prevalence of guideline-directed medical therapy among patients receiving cardiac resynchronization therapy defibrillator implantation in the National Cardiovascular Data Registry during the years 2006 to 2008. Am J Cardiol. 2014 Jun 15; 113(12):2052-6.
Score: 0.016
-
Dodson JA, Reynolds MR, Bao H, Al-Khatib SM, Peterson ED, Kremers MS, Mirro MJ, Curtis JP. Developing a risk model for in-hospital adverse events following implantable cardioverter-defibrillator implantation: a report from the NCDR (National Cardiovascular Data Registry). J Am Coll Cardiol. 2014 Mar 04; 63(8):788-96.
Score: 0.016
-
Lim DS, Reynolds MR, Feldman T, Kar S, Herrmann HC, Wang A, Whitlow PL, Gray WA, Grayburn P, Mack MJ, Glower DD. Improved functional status and quality of life in prohibitive surgical risk patients with degenerative mitral regurgitation after transcatheter mitral valve repair. J Am Coll Cardiol. 2014 Jul 15; 64(2):182-92.
Score: 0.016
-
Kremers MS, Hammill SC, Berul CI, Koutras C, Curtis JS, Wang Y, Beachy J, Blum Meisnere L, Conyers del M, Reynolds MR, Heidenreich PA, Al-Khatib SM, Pina IL, Blake K, Norine Walsh M, Wilkoff BL, Shalaby A, Masoudi FA, Rumsfeld J. The National ICD Registry Report: version 2.1 including leads and pediatrics for years 2010 and 2011. Heart Rhythm. 2013 Apr; 10(4):e59-65.
Score: 0.015
-
Tung R, Josephson ME, Reddy V, Reynolds MR. Influence of clinical and procedural predictors on ventricular tachycardia ablation outcomes: an analysis from the substrate mapping and ablation in Sinus Rhythm to Halt Ventricular Tachycardia Trial (SMASH-VT). J Cardiovasc Electrophysiol. 2010 Jul; 21(7):799-803.
Score: 0.012